• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

    9/25/25 5:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • New AA (Allergan Aesthetics) Signature™ multimodal treatment approach to be presented at AMWC Dubai following successful launch in 25 countries so far this year.
    • Experts to explore the paradigm shift in medical aesthetics and decode new AA Signature™ approach at Allergan Medical Institute (AMI) symposium.
    • Skin Quality Multimodal Mastery explored in depth at Global Medical Affairs symposium as part of Allergan Aesthetics' continued commitment to advancing skin quality.

    IRVINE, Calif., Sept. 25, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.

    The AA Signature™ treatment approach harnesses Allergan Aesthetics' leading product portfolio and is supported by advanced education and business resources for healthcare professionals. Designed to meet evolving patient needs and enhance clinical practice, AA Signature™ has been successfully launched in over 25 countries* this year and is planned for further expansion. The protocol-driven methodology currently addresses different globally recognized patient needs including Lift Up, Distinct Definition, and improved skin quality.

    "Aesthetic trends worldwide are shifting toward a more natural, individualized look. The AA Signature™ treatment approach is designed to meet these emerging patient needs, offering a holistic method that recognizes and aligns with each patient's unique goals. The approach leverages Allergan Aesthetics' advanced and versatile portfolio to empower healthcare professionals to deliver multimodal treatment plans for tailored results, strengthening patient relationships and encouraging long-term retention," said Mark Wilson, SVP, International Allergan Aesthetics. We've received excellent feedback from healthcare practitioners since launching AA Signature™, and we look forward to continuing to showcase real-world results and data in the coming months."

    AMWC Dubai 2025 AMI Symposium

    The Allergan Medical Institute hosted symposium 'Design your patients' look with the NEW Signature approach by Allergan Aesthetics and a decade of MD Codes™ excellence' will take place at 11AM-1PM on Wednesday, 1 October in Baniyas Ballroom 1, Grand Hyatt Dubai.

    World-renowned experts including plastic surgeon and creator of the MD Codes™ system Dr Mauricio de Maio will explore the paradigm shift in medical aesthetics and decode the new AA Signature™ approach.

    A live injection of AA Signature™ Lift Up will be performed, focusing on how the multimodal approach can help address patient needs including added lift, structure and skin firmness as research finds patients long for a lifted and more defined appearance1,2†.

    Allergan Aesthetics Global Medical Affairs Symposium on Skin Quality Multimodal Mastery

    A single-strategy treatment plan may not be enough to unlock the skin's full potential7, and a multimodal approach is the focus of this year's medical symposium, 'Mastering Skin Quality - Integrating Aesthetic Modalities for Holistic Skin Quality Improvement' on Wednesday, 1 October at 2PM-4PM in Al Ameera Ballroom 2, Grand Hyatt Dubai.

    With 94% of people wanting to improve their facial skin quality3‡, Allergan Aesthetics brings together globally renowned leaders in aesthetics Dr. Rami Abadi, Dr. Sylwia Godlewska, Dr. Maurizio Cavallini and Dr. Mansi Mukherjee to offer a deep dive into understanding patient needs related to skin quality and exploring the integration of a holistic, multi-modal aesthetic approach—including hyaluronic acid (HA), biostimulators, and hybrid injectables—within clinical practice to enhance skin quality and elevate patient satisfaction.

    Meet The Experts

    Allergan Aesthetics will host a series of Meet the Experts sessions live from booth B100 across the three day event, featuring:

    • Predictable, proven, preferred with Dr Mansi Mukherjee and Prof Yehia El Garem
    • From patients' needs to practice: Enhancing long term value with AA Signature™ with Dr Akiko Imaizumi and Dr Rami Abadi
    • SKIN360 by AA Signature™ with Dr Raafat Lakis and Dr Minoka Nadesan
    • LIFT UP by AA Signature™ with Dr Sami Alissa and Dr Wei-Ting Chang

    Allergan Aesthetics Booth – B100

    Attendees can discover more about the AA Signature approach and explore the Allergan Aesthetics facial aesthetics portfolio with immersive product experiences at networking opportunities at the booth.

    New clinical data 

    Additionally, a personalized aesthetics approach and skin quality are topics that feature amongst 7 e-posters that have been accepted across various products, treatments and indications, furthering Allergan Aesthetics' commitment. Titles and authors include:

    Presentation Topic

    Poster Title

    Authors

    MaxDiff Characteristics Likely to Treat - Middle Eastern Women ABS

    Facial and Body Aesthetic Concerns and Treatment Interests Among Middle Eastern Women: Results From Middle Eastern Female-Identifying Respondents of a Large US Survey of Aesthetically Inclined Adults

    Raafat Lakis, Mona Sadeghpour, Omer Ibrahim, Amir Moradi, Mohammad Saleh Al-Khowailed, Ammar Raza, Nazanin Ashourian, Elena Dimitrijevic, Sara Sangha

    Personalized Ax - Lift

    Personalized Aesthetic Treatment for Nonsurgical Lift Effect Using Multimodal Portfolio of Injectables

    Juliana Chieppe; Jake Sloane; Peter Peng; Emily Schultz; Wang Ye; Ahmed Yasin

    Personalized Ax - Skin

    Personalized Aesthetic Treatment to Improve Common Skin Quality Needs Using a Multimodal Portfolio of Injectables

    Jake Sloane; Juliana Chieppe; Yuexing Song; Peter Peng; Emily Schultz; Ahmed Yasin

    Juvéderm® VYCROSS™, BOTOX® upper and midface treatment and PROs

    Infraorbital and Periorbital Rejuvenation with Sequential Use of Hyaluronic Acid Fillers and OnabotulinumtoxinA

    Gregory Goodman; Frank Lin; Samira Baharlou; Sarah Boxley; Pierre Cuvelier; Cara McDonald; Joan Vandeputte; Ivar Van Heijningen; Julia K. Garcia; Traci Baker; Smita Chawla; Carola de la Guardia

    Juvéderm® VOLUMA temple China study

    Improvement in Temple Hollowing With VYC-20L Filler: A Multicenter, Randomized Controlled Trial of Safety and Effectiveness in a Chinese Population

    Yun Xie, Qingfeng Li, Jiaming Sun, Lei Wang, Qian Tan, Chengyuan Wang, Dong Li, Hongyi Zhao, Chenliang Deng, Jingli Shi, Smita Chawla

    Juvéderm® VOLUMA temple repeat treatment and PROs from US study

    Efficacy and Safety of VYC-20L Hyaluronic Acid Filler in Temple Hollowing: Initial Treatment and Maintenance Results from a Multicenter Study

    José R. Montes, Derek Jones, Brian Biesman, Kenneth Beer, Deirdre Hooper, Steve Yoelin, Leslie Baumann, Kelly Leung, Shirley Chung, Smita Chawla

    HArmonyCa™ Int'l Interim

    An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation

    A Nikolis, N Demosthenous, S Humphrey, F Urdiales, M Salomon, A Schumacher

     

    Notes to Editors

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit. www.allerganaesthetics.com.

    Forward-Looking Statements 

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

    Global Media:

    Investors:

    Michael Salzillo

    Liz Shea

    [email protected] 

    [email protected]  





    U.S. Media:



    Adelle Infante



    [email protected]  



    Disclaimers

    Material developed and funded by Allergan Aesthetics, an AbbVie company.

    Copyright 2023 AbbVie. All rights reserved. All trademarks are the property of their respective owners.

    Footnotes:

    *AA Signature has rolled out in the following 25 countries so far this year: Spain / Iberia, Turkey, Brazil, Australia, Taiwan, France, Mexico, Columbia, Argentina, Chile, Italy, Bulgaria, Sweden, Finland, Denmark, Norway, China, GULF, South Africa, and other Central and Eastern Europe countries.    

    †Qualitative data from an online community platform captured over 5 days with a range of consumer types (naïve considerers, engaged considerers, users) from a range of ages (20–34, 34–49 and 50+) from Canada, Brazil, China.

    ‡94% of 14,584 people interviewed in a global survey. People desired to improve their facial skin, and terms such as radiance and healthy, glowing skin were requested by patients seeking improvements in their appearance. The term 'skin quality' encompasses this collection of desired outcomes.  

    References:

    1. Chiu A et al. Clin Cosmet Investig Dermatol. 2023;16:1521–32.
    2. Allergan Aesthetics. Data on File. Consumer Filler. March 2021.
    3. Allergan Aesthetics. Data on file. REF-100241. Skin Health Media Statistics. August 2022.
    4. Allergan Aesthetics. Data on file. Consumer Beauty Insights Survey 2021. August 2021.
    5. Beauty Independent. Forget Beauty. These Days, Skincare Is All About Health. But What Exactly Is Skin Health? Available at: https://www.beautyindependent.com/skincare-what-exactly-skin-health/. [Accessed September 2024]. 
    6. Allergan Aesthetics. Data on File. The Lower Face Customer & HCP Journey: Qualitative Research Report. May 2024.
    7. Goldie K et al. Clin Cosmet Investig Dermatol 2021;14:643–54.
    8. Humphrey S, et al. Dermatol Surg. 2021;47(7):974–81. 

     

    Allergan Aesthetics Logo (PRNewsfoto/AbbVie)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-to-showcase-multimodal-treatment-approach-and-continued-commitment-to-skin-quality-at-amwc-dubai-302565990.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    9/17/2025$270.00Hold → Buy
    Berenberg
    8/12/2025$231.00Overweight
    Piper Sandler
    8/7/2025$214.00Neutral → Outperform
    Daiwa Securities
    5/14/2025$205.00Buy → Neutral
    Citigroup
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie upgraded by Berenberg with a new price target

    Berenberg upgraded AbbVie from Hold to Buy and set a new price target of $270.00

    9/17/25 7:51:43 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on AbbVie with a new price target

    Piper Sandler resumed coverage of AbbVie with a rating of Overweight and set a new price target of $231.00

    8/12/25 8:00:24 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded AbbVie from Neutral to Outperform and set a new price target of $214.00

    8/7/25 7:30:45 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CHIEF OPERATIONS OFFICER Saleki-Gerhardt Azita sold $8,407,055 worth of shares (42,370 units at $198.42) and exercised 42,370 shares at a strike of $54.86 (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    8/14/25 5:00:06 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $2,639,253 worth of shares (13,295 units at $198.51), decreasing direct ownership by 19% to 58,247 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    8/7/25 5:00:06 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Crum Demetris D claimed ownership of 7,048 shares (SEC Form 3)

    3/A - AbbVie Inc. (0001551152) (Issuer)

    7/30/25 5:00:26 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

    – BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The submission is based on data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of PVEK in BPDCN. BPDCN is a rare and aggressive blood cancer that has features of both leukemia and lymphoma. Patients typically present with skin lesions and the disease often spreads to the bone marrow

    9/30/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

    New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicinesFacility expected to be fully operational and serving patients by 2027Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturingNORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity.

    9/29/25 12:00:00 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

    The list price will be consistent with the United States to reflect the value of the innovationAbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in improving patient outcomes, consistent with the level of recognition in the United StatesNORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal can

    9/29/25 9:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    9/11/25 7:30:54 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    8/22/25 6:02:07 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by AbbVie Inc.

    144 - AbbVie Inc. (0001551152) (Subject)

    8/21/25 6:04:39 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share.   The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025.  Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We

    9/5/25 9:07:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Second-Quarter 2025 Financial Results

    Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to Acquired IPR&D and Milestones Expense   Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9.5 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.423 Billion; Global Rinvoq Net Revenues Were $2.028 Billion; Global Humira Net Reven

    7/31/25 7:44:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Second-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

    6/30/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care